Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

76.87 -0.64 (-0.82%)
Streaming Delayed Price Updated: 12:42 PM EDT, Oct 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Astrazeneca Plc ADR

< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
48 49 Next >
Second Sight Medical To Merge With AstraZeneca-Backed Nano Precision Medical
Second Sight Medical Products Inc (NASDAQ: EYES) will acquire privately-held Nano Precision Medical Inc in an all-stock transaction. Second Sight Medical... 
Via Benzinga
Key Events This Week: All Eyes On The CPI
After what DB's Jim Reid describes as 
Via Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
AstraZeneca Dumps Off Mid-Stage Cardiovascular Drug To Regio Biosciences
AstraZeneca plc (NASDAQ: AZN) has granted  
Via Benzinga
4 Great Global Stocks to Buy for a Diversified Portfolio
Global stocks that are worth holding for the long-term for a well-diversified portfolio. High growth global stocks with strong fundamentals. 
Via InvestorPlace
Avoid Novavax for Now, Until the Picture Clears Up
NVAX stock may have seen a near-term bounce following the completion of filing of EUA filing with the FDA, but it may not be a buy yet. 
Via InvestorPlace
7 Stocks to Watch in This Current Earnings Season
In these inflationary times, analysts predict robust earnings growth especially in old economy stocks. Here are seven names to consider. 
Via InvestorPlace
Valneva Advances Booster Phase Of Its Cov-Compare COVID-19 Vaccine Trial
Valneva SE (NASDAQ: VALN) has started booster vaccinations in adult participants from its Phase 3 pivotal trial, Cov-Compare. This booster extension is... 
Via Benzinga
Markets Fears
Today markets dropped precipitously over fear of a Ukrainian invasion and higher interest rates and inflation. 
Via Talk Markets
Analysis: Why Is It So Difficult To Obtain COVID-19 Monoclonal Antibody Treatments?
The demand for monoclonal antibody treatments to help in the recovery of COVID-19 patients has outpaced the supply, and this situation runs the risk of becoming more acute as... 
Via Benzinga
Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
A third booster dose of a COVID-19 vaccine from either AstraZeneca Plc (NASDAQ: AZN), Pfizer Inc (NYSE: PFE) - BioNTech SE (NASDAQ: BNTX), or ... 
Via Benzinga
Ionis' Eplontersen Receives FDA Orphan Drug Status For Misfolded Protein Disorder
The FDA has granted orphan drug designation to Ionis Pharmaceuticals Inc's (NASDAQ: IONS) eplontersen, an investigational antisense medicine for... 
Via Benzinga
Lower COVID-19 Vaccine Sales Estimated Amid Less Severe Omicron Variant: Bloomberg
According to an analytics firm, Airfinity Ltd, evidence that omicron causes less-severe disease than earlier COVID-19 variants is expected to lower the growth in vaccine... 
Via Benzinga
7 Bull Market Stocks to Buy for a Continued Run Higher in 2022
Despite surging inflation and the anticipated increase in interest rates, these bull market stocks deserve your attention. 
Via InvestorPlace
7 Bear Market Stocks to Buy If You See Trouble Ahead
These bear market stocks provide capital protection in a sharp correction scenario. They also typically have a healthy dividend yield. 
Via InvestorPlace
AstraZeneca Rolls Out "Unprecedented' Three Year Survival Data For Imfinzi/Treme Combo In Liver Cancer
A combination of tremelimumab and AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab) extended the lives of newly diagnosed patients with unresectable... 
Via Benzinga
Death Cross Looms Over AstraZeneca Investors
If history is any guide, there may be trouble ahead for shares of AstraZeneca (NASDAQ:AZN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
Chopped Stocks
The day's theme is sell tech and buy banks. 
Via Talk Markets
The Week Ahead In Biotech (Jan. 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Here are the key catalysts... 
Via Talk Markets
The Week Ahead In Biotech (Jan 16-22): Focus On Data Presentations And IPOs In Holiday-Shortened Week
Biotech stocks posted losses for the third straight week, as the sector reacted to broader market weakness and announcements out of the 2022 JPMorgan Healthcare conference. Swiss... 
Via Benzinga
Novavax Still Has Not Received an FDA EUA as the Market Waits
NVAX stock looks like a good buy here, especially if analysts' revenue forecasts for 2022 come to pass as forecast and NVAX bounces back. 
Via InvestorPlace
Two Curses Of The Current Year
The good news on inflation after this week's shocker is that December wholesale prices only rose 0.2%. 
Via Talk Markets
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio... 
Via Benzinga
AstraZeneca Sells Additional Half-Million Doses Of Its COVID-19 Antibody To US
AstraZeneca Plc (NASDAQ: AZN) said the U.S. government has agreed to purchase an additional 500,000 doses of its antibody cocktail, Evusheld, used to prevent COVID-... 
Via Benzinga
AstraZeneca's COVID-19 Vaccine Booster Against Omicron, Delta - New Data Supports Use
AstraZeneca Plc (NASDAQ: AZN) has posted preliminary data from an ongoing safety and immunogenicity trial of its COVID-19 shot, Vaxzevria. When given as a third... 
Via Benzinga
Adagio's COVID-19 Antibody Has Neutralizing Activity Comparable To Other Antibodies
Adagio Therapeutics Inc (NASDAQ: ADGI) shares gain during the premarket session after recent findings showing that ADG20 has neutralization activity against the omicron... 
Via Benzinga
Scorpion Therapeutics, AstraZeneca Ink Precision Medicines Pact For Hard-To-Target Cancer Proteins
AstraZeneca Plc (NASDAQ: AZN) has signed a collaboration agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines... 
Via Benzinga
The Daily Biotech Pulse: Illunina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo... 
Via Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
Cannabis Movers & Shakers: Aurora Bolsters Management, Curaleaf Names New Pres, Verano & Avicanna's New Appointments
Aurora Announces Changes To Management Team Aurora Cannabis Inc. (NASDAQ: 
Via Benzinga
< Previous 1 2
...
28 29 30 31 32 33 34 35 36
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.